AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 MAR 31 - (NewsRx.com & NewsRx.net) -- Researchers review prospects for new tuberculosis vaccines in a recent issue of the International Journal of Tuberculosis and Lung Disease.
According to recent research from Switzerland, "Research towards the development of improved TB vaccines has reached an important turning point. A large number of vaccine candidates such as modified BCG, attenuated Mycobacterium tuberculosis and protein or DNA subunit vaccines, resulting from over a decade of work in experimental laboratory models, are now getting ready for clinical testing. The transition from laboratory to clinical trials has a wide range of strategic and technical implications."
"Facilities and funding need to be identified for the production of clinical vaccine lots, an issue that is difficult to tackle due to the live organisms in some of the new vaccine candidates; regulatory hurdles need to be overcome; protocols and trial sites need to be developed, for phase III clinical efficacy trials in particular," reported Uli Fruth at the World Health Organization in Switzerland and Douglas B. Young at University College London in the U.K.
"The Stop TB Working Group on TB Vaccine Development provides a global forum that brings ...
Source: HighBeam Research, Prospects for new tuberculosis vaccines reviewed.